Osimertinib clinical trials
Also written AZD9291 and Tagrisso.
ClinicalTrials.gov finds 393 studies for osimertinib. How that becomes 130 here
Every study that search finds has been read, apart from the 1 newest, to see whether and how it gives osimertinib. ClinicalTrials.gov counts as of Nov 17, 2026. How drug pages count
- 393Found by its intervention search · See all 393 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 302 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −35
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- T790M Mutation Positive 2nd Line STandard of cAre RegistryNCT02368990 · Chemotherapy after an earlier TKI; not givenReport a problem
- TAURAS - T790 AURA ScreenFailure SOC Registry StudyNCT02405247 · Screen failures for an osimertinib trial; not givenReport a problem
- A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung CancerNCT02424617 · Earlier treatment, not given in this studyReport a problem
- Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationNCT03318939 · Earlier treatment, not given in this studyReport a problem
- A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung CancerNCT03446417 · Named for eligibility only; not givenReport a problem
- EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR MutationsNCT03516214 · Earlier treatment, not given in this studyReport a problem
- PDX Models From EGFR Mutant TumorsNCT03872440 · Earlier treatment; tumour models studiedReport a problem
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerNCT04077463 · Earlier treatment, not given in this studyReport a problem
- Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving OsimertinibNCT04099836 · Earlier treatment, not given in this studyReport a problem
- Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLCNCT04136535 · Earlier treatment, not given in this studyReport a problem
- Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib ResistanceNCT04316351 · Earlier treatment, not given in this studyReport a problem
- Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical StudyNCT04517526 · Earlier treatment, not given in this studyReport a problem
- Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.NCT04737382 · Earlier treatment; resistance analysedReport a problem
- Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib TreatmentNCT04882345 · Earlier treatment, not given in this studyReport a problem
- A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureNCT04988295 · Earlier treatment, not given in this studyReport a problem
- Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).NCT05219162 · Earlier treatment; gene profile at progressionReport a problem
- Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsNCT05256290 · Earlier treatment, not given in this studyReport a problem
- Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsNCT05364073 · Earlier treatment, not given in this studyReport a problem
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerNCT05388669 · Earlier treatment, not given in this studyReport a problem
- Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain MetastasesNCT05477615 · Earlier treatment, not given in this studyReport a problem
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT05498428 · Earlier treatment, not given in this studyReport a problem
- Premedication to Reduce Amivantamab Associated Infusion Related ReactionsNCT05663866 · Earlier treatment, not given in this studyReport a problem
- Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLCNCT05805631 · Earlier treatment, not given in this studyReport a problem
- The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLCNCT06117644 · Earlier treatment, not given in this studyReport a problem
- AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLCNCT06196814 · Earlier treatment, not given in this studyReport a problem
- Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.NCT06296745 · Earlier treatment, not given in this studyReport a problem
- High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With OsimertinibNCT06394674 · Earlier treatment, not given in this studyReport a problem
- A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung CancerNCT06868485 · Earlier treatment, not given in this studyReport a problem
- Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080 · Earlier treatment, not given in this studyReport a problem
- An External Control Arm Study in Non-Small Cell Lung CancerNCT07174388 · Earlier treatment, not given in this studyReport a problem
- The HER Project: HRD in EGFR-mutated NSCLCNCT07303218 · Mentioned from laboratory work; not givenReport a problem
- An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver MetastasesNCT07461727 · Named for eligibility only; not givenReport a problem
- Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)NCT07507188 · Earlier treatment, not given in this studyReport a problem
- Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung CancerNCT07563205 · Earlier treatment, not given in this studyReport a problem
- A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung CancerNCT07699328 · Earlier treatment, not given in this studyReport a problem
- 358Give osimertinib to participants
- −58Observe patients on it, or give it outside a trial
- −2Use it as a tool: an imaging tracer or a test of drug response
- −17Compare another treatment with it
- −151Give it beside what is tested
- 130Test it: the count on this site
Get an email when these change. Save the osimertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 13 Nov 2015 · TAGRISSO · NDA 208065 (FDA, Drugs@FDA)
- European Union
- 1 Feb 2016 · Tagrisso · EMEA/H/C/004124 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
129 studies that test it; most in 2018 (16); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 13 |
| 2015 | 12 |
| 2016 | 12 |
| 2017 | 8 |
| 2018 | 16 |
| 2019 | 8 |
| 2020 | 11 |
| 2021 | 10 |
| 2022 | 12 |
| 2023 | 7 |
| 2024 | 9 |
| 2025 | 3 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 46 · Other 84
AstraZeneca (43) · National Cancer Institute (NCI) (4) · Samsung Medical Center (4) · Jonsson Comprehensive Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Qingdao Central Hospital (3) · Dana-Farber Cancer Institute (2) · Eli Lilly and Company (2)
Often tested with
Tested in the same studies.
Durvalumab (6) · Pemetrexed (5) · Carboplatin (4) · Afatinib (3) · Capivasertib (3) · Crizotinib (3) · Necitumumab (3) · Dacomitinib (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 5 phase 3 studies under way
Osimertinib is the comparator. A study of two new drugs counts under both.
- 2Aflutinib · ArriVent BioPharma, Inc., Allist Pharmaceuticals, Inc. · next primary completion Feb 2029
- 1Amivantamab · Janssen Research & Development, LLC
- 1Lazertinib · Janssen Research & Development, LLC
- 1ASKC202 · Jiangsu Aosaikang Pharmaceutical Co., Ltd. · next primary completion Dec 2030
- 1EGFR Inhibitor TY-9591 · TYK Medicines, Inc
New treatments tested with it · 8 most studied
New when their studies opened, with osimertinib beside them; studies of each.
Reaching primary completion within a year · 14, 2 in phase 3
Studies that test osimertinib, phase 3 first.
- Feb 2027Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)Phase 3 · AstraZeneca
- Aug 2027A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionPhase 3 · AstraZeneca
- Dec 2026Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerPhase 1/2 · Jonsson Comprehensive Cancer Center
- Dec 2026Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationPhase 2 · Hunan Province Tumor Hospital
- Feb 2027Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerPhase 2 · Jonsson Comprehensive Cancer Center
- Jun 2027A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung CancersPhase 1 · Memorial Sloan Kettering Cancer Center
- Jun 2027Boosting Osimertinib Blood Brain Barrier PenetrationPhase 2 · Maastricht University Medical Center
- Jun 2027Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorPhase 1 · National Cancer Institute (NCI)
- Jun 2027Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangePhase 2 · National Cancer Institute (NCI)
- Jul 2027Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With CobicistatPhase 4 · Maastricht University Medical Center
Studies
Open first, then newest update. How each study uses osimertinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 130
- Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With CobicistatRecruitingPhase 4Maastricht University Medical CenterNCT05748093Exposure and cost boosted with cobicistatReport a problem
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeRecruitingPhase 2National Cancer Institute (NCI)NCT03191149In EGFR exon 20 insertionsWritten as OsimertinibReport a problem
- Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm StudyRecruitingPhase 2AstraZenecaNCT07295821Induction and maintenance when chemotherapy is not possibleWritten as OsimertinibReport a problem
- Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.RecruitingPhase 4AstraZenecaNCT07279935With chemotherapy after recurrence on adjuvant treatmentReport a problem
- Lurbinectedin With Osimertinib in Transformed Small Cell Lung CancerRecruitingPhase 1/2Misty ShieldsNCT07153055With lurbinectedin in transformed small cell lung cancerWritten as OsimertinibReport a problem
- Boosting Osimertinib Blood Brain Barrier PenetrationRecruitingPhase 2Maastricht University Medical CenterNCT07485452With febuxostat to raise brain penetrationWritten as Osimertinib & febuxostatReport a problem
- EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyRecruitingPhase 3Region SkaneNCT06486142Sequence against afatinib or dacomitinib firstWritten as OsimertinibReport a problem
- Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)RecruitingPhase 2Samsung Medical CenterNCT04591002Against observation for ground-glass nodulesWritten as Osimertinib 80 MGReport a problem
- Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung AdenocarcinomaRecruitingPhase 2Samsung Medical CenterNCT05528458Against observation for remaining ground-glass nodulesWritten as Osimertinib 80Mg TabReport a problem
- Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudyRecruitingNot applicableSecond Affiliated Hospital of Nanchang UniversityNCT07398599Double dose with bevacizumab and intrathecal chemotherapyReport a problem
- Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07323641With telisotuzumab vedotinWritten as OsimertinibReport a problem
- Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L OsimertinibNot yet recruitingPhase 1/2Shanxi Province Cancer HospitalNCT07486648With capivasertib after first-line progressionWritten as Capivasertib in combination with OsimertinibReport a problem
- A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLCRecruitingPhase 2Shanghai Chest HospitalNCT07058519Adaptive treatment guided by ctDNAWritten as Osimertinib 80 MGReport a problem
- Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung AdenocarcinomaNot yet recruitingPhase 2The University of Hong KongNCT06918782With chemotherapy in poor-prognosis patientsReport a problem
- Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)RecruitingPhase 2Goethe UniversityNCT05281406With chemotherapy when ctDNA persists (PACE)Written as OsimertinibReport a problem
- Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant OsimertinibRecruitingPhase 2Jair Bar, M.D., Ph.D.NCT06206850Before surgery, resistance mechanisms studiedWritten as OsimertinibReport a problem
- Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNot yet recruitingNot applicableGuangdong Association of Clinical TrialsNCT06709274Adjuvant for MRD-positive EGFR-mutant stage IWritten as OsimertinibReport a problem
- Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line RechallengeRecruitingPhase 2Mark VincentNCT04335292Rechallenge in third line after chemotherapyReport a problem
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingPhase 2Hunan Province Tumor HospitalNCT04322890One matched treatment in an oncogene cohort studyWritten as OsimertinibReport a problem
- A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical SurgeryNot yet recruitingPhase 2Jin YingNCT06530719After progression on an earlier EGFR TKIWritten as Osimertinib mesylateReport a problem
See all 130 studies that test osimertinib →
Behind its US label · 5 — the studies the FDA label of TAGRISSO describes
From the Clinical Studies section of TAGRISSO (2024-09), as openFDA has it. A study the site does not hold is left out.
- AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedPhase 3AstraZenecaNCT02151981Report a problem
- AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCompletedPhase 3AstraZenecaNCT02296125Report a problem
- AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.Active, not recruitingPhase 3AstraZenecaNCT02511106Report a problem
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)Active, not recruitingPhase 3AstraZenecaNCT03521154Report a problem
- A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Active, not recruitingPhase 3AstraZenecaNCT04035486Report a problem
Tested on its own · 65 — no other medicine in its arm
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeRecruitingPhase 2National Cancer Institute (NCI)NCT03191149In EGFR exon 20 insertionsWritten as OsimertinibReport a problem
- Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm StudyRecruitingPhase 2AstraZenecaNCT07295821Induction and maintenance when chemotherapy is not possibleWritten as OsimertinibReport a problem
- Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)RecruitingPhase 2Samsung Medical CenterNCT04591002Against observation for ground-glass nodulesWritten as Osimertinib 80 MGReport a problem
- Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung AdenocarcinomaRecruitingPhase 2Samsung Medical CenterNCT05528458Against observation for remaining ground-glass nodulesWritten as Osimertinib 80Mg TabReport a problem
- Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant OsimertinibRecruitingPhase 2Jair Bar, M.D., Ph.D.NCT06206850Before surgery, resistance mechanisms studiedWritten as OsimertinibReport a problem
- A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical SurgeryNot yet recruitingPhase 2Jin YingNCT06530719After progression on an earlier EGFR TKIWritten as Osimertinib mesylateReport a problem
- Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLCNot yet recruitingPhase 2Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT06436144With etoposide for primary resistanceWritten as OsimertinibReport a problem
- Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell CarcinomaRecruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT06383728Before surgery in squamous lung cancerWritten as OsimertinibReport a problem
- Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)Not yet recruitingPhase 3Fudan UniversityNCT06323148Adjuvant guided by ctDNA, against no treatmentWritten as OsimertinibReport a problem
- Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)RecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT05686434Adjuvant in high-risk stage I (OSTAR)Written as OsimertinibReport a problem
- Adjuvant Treatment Based on MRD for EGFR Mutant NSCLCRecruitingPhase 2Guangdong Association of Clinical TrialsNCT05536505Adjuvant when MRD is foundReport a problem
- A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR MutationsRecruitingNot applicableYonsei UniversityNCT04816838Before surgery, drug-tolerant persister cells studiedWritten as OsimertinibReport a problem
- Osimertinib In EGFR Mutant Lung CancerActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT03586453Alone in EGFR-mutant lung cancerWritten as OsimertinibReport a problem
- Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06303167One matched subprotocol in NCI-MATCHWritten as OsimertinibReport a problem
- Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRmActive, not recruitingPhase 2AstraZenecaNCT05546866Adjuvant in uncommon EGFR mutationsWritten as OsimertinibReport a problem
- Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)CompletedPhase 2Sehhoon ParkNCT0456387180 mg in EGFR-mutant lung cancerWritten as 80mg OsimertinibReport a problem
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)Active, not recruitingPhase 3AstraZenecaNCT05629234Continued for people from earlier studies (ROSY-T)Written as OsimertinibReport a problem
- A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3AstraZenecaNCT04765059Continued with chemotherapy after progression, against placebo (COMPEL)Written as Osimertinib (AZD9291) pemetrexed cisplatin or carboplatinReport a problem
- A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionActive, not recruitingPhase 3AstraZenecaNCT05120349Adjuvant against placebo in stage IA (ADAURA2)Written as OsimertinibReport a problem
- Whole Genomic Landscape of Advanced EGFR-mutant NSCLCActive, not recruitingNot applicableSeoul National University HospitalNCT03969823Genomic landscape of resistance during treatmentWritten as TagrissoReport a problem
Showing 20 of 65. See all 65 →
Tested with established drugs · 11 — they are given beside it
- Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)RecruitingPhase 2Goethe UniversityNCT05281406With chemotherapy when ctDNA persists (PACE)Written as OsimertinibReport a problem
- Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLCRecruitingPhase 2Sun Yat-sen UniversityNCT05011487With chemotherapy before surgery in stage IIIWritten as OsimertinibReport a problem
- To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsActive, not recruitingPhase 2AstraZenecaNCT06194448Induction before chemoradiation, then maintenanceWritten as OsimertinibReport a problem
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)Active, not recruitingPhase 3AstraZenecaNCT03521154On the US labelAgainst placebo after chemoradiation (LAURA)Written as Osimertinib 80mg/40mgReport a problem
- A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)Active, not recruitingPhase 2AstraZenecaNCT05526755Five years of adjuvant treatmentWritten as Osimertinib 80 mg/40 mgReport a problem
- Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)CompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT02856893Upfront or after gefitinib, switch guided by ctDNA (APPLE)Written as OsimertinibReport a problem
- Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)CompletedPhase 1AstraZenecaNCT02157883Interaction with itraconazoleWritten as AZD9291Report a problem
- AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedPhase 3AstraZenecaNCT02151981On the US labelAgainst platinum chemotherapy after an EGFR TKI (AURA3)Report a problem
- Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLCCompletedPhase 1AstraZenecaNCT02908750Effect on fexofenadine levelsWritten as Osimertininb tablet dosingReport a problem
- Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLCCompletedPhase 1AstraZenecaNCT02197247Interaction with rifampicinWritten as AZD9291 tablet dosingReport a problem
- Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung CancerCompletedPhase 1AstraZenecaNCT02317016Effect on rosuvastatin levelsWritten as AZD9291 tablet dosingReport a problem
Tested in a combination · 54 — another drug in the study is under test too
- Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With CobicistatRecruitingPhase 4Maastricht University Medical CenterNCT05748093Exposure and cost boosted with cobicistatReport a problem
- Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.RecruitingPhase 4AstraZenecaNCT07279935With chemotherapy after recurrence on adjuvant treatmentReport a problem
- Lurbinectedin With Osimertinib in Transformed Small Cell Lung CancerRecruitingPhase 1/2Misty ShieldsNCT07153055With lurbinectedin in transformed small cell lung cancerWritten as OsimertinibReport a problem
- Boosting Osimertinib Blood Brain Barrier PenetrationRecruitingPhase 2Maastricht University Medical CenterNCT07485452With febuxostat to raise brain penetrationWritten as Osimertinib & febuxostatReport a problem
- EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyRecruitingPhase 3Region SkaneNCT06486142Sequence against afatinib or dacomitinib firstWritten as OsimertinibReport a problem
- Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudyRecruitingNot applicableSecond Affiliated Hospital of Nanchang UniversityNCT07398599Double dose with bevacizumab and intrathecal chemotherapyReport a problem
- Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07323641With telisotuzumab vedotinWritten as OsimertinibReport a problem
- Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L OsimertinibNot yet recruitingPhase 1/2Shanxi Province Cancer HospitalNCT07486648With capivasertib after first-line progressionWritten as Capivasertib in combination with OsimertinibReport a problem
- A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLCRecruitingPhase 2Shanghai Chest HospitalNCT07058519Adaptive treatment guided by ctDNAWritten as Osimertinib 80 MGReport a problem
- Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung AdenocarcinomaNot yet recruitingPhase 2The University of Hong KongNCT06918782With chemotherapy in poor-prognosis patientsReport a problem
- Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNot yet recruitingNot applicableGuangdong Association of Clinical TrialsNCT06709274Adjuvant for MRD-positive EGFR-mutant stage IWritten as OsimertinibReport a problem
- Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line RechallengeRecruitingPhase 2Mark VincentNCT04335292Rechallenge in third line after chemotherapyReport a problem
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingPhase 2Hunan Province Tumor HospitalNCT04322890One matched treatment in an oncogene cohort studyWritten as OsimertinibReport a problem
- Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNot yet recruitingPhase 1Jonathan RiessNCT06067776With cetuximab and tucatinibWritten as OsimertinibReport a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060One matched subprotocol in NCI-MATCHWritten as OsimertinibReport a problem
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02496663With necitumumab after progressionWritten as OsimertinibReport a problem
- Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationActive, not recruitingPhase 3AstraZenecaNCT03833154After SBRT in one single-arm cohort (PACIFIC-4)Report a problem
- AZD9291 in Combination With Ascending Doses of Novel TherapeuticsActive, not recruitingPhase 1AstraZenecaNCT02143466With durvalumab, savolitinib or selumetinib, before approval (TATTON)Report a problem
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingPhase 1/2Dana-Farber Cancer InstituteNCT03122717With gefitinib, first-lineWritten as OsimertinibReport a problem
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingPhase 3Eli Lilly and CompanyNCT02411448With ramucirumab in one exploratory partWritten as OsimertinibReport a problem
Showing 20 of 54. See all 54 →
Beside an established treatment under test · 42 — an approved drug, surgery or radiation is what the study tests
Tested with osimertinib: Radiation 13 · Surgery or a procedure 8 · Pemetrexed 5 · Bevacizumab 4 · Carboplatin 3 · Aspirin 2 · Cisplatin 1 · Ramucirumab 1
- Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain MetastasesRecruitingPhase 2Cho Ray HospitalNCT07911449In every armContinued while radiosurgery is added for brain metastasesWritten as OsimertinibReport a problem
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerRecruitingPhase 3National Cancer Institute (NCI)NCT04181060In every armBoth arms take it while bevacizumab is addedWritten as OsimertinibReport a problem
- Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung CarcinomaRecruitingPhase 2City of Hope Medical CenterNCT06014827In every armContinued while radiation is added for oligoprogressionWritten as OsimertinibReport a problem
- A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the BrainRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06741085In every armBoth arms take it while radiosurgery is addedWritten as osimertinibReport a problem
- Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLCRecruitingPhase 2NYU Langone HealthNCT07874490In every armBoth arms take it while cyclosporine A is addedWritten as OsimertinibReport a problem
- OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic TherapyRecruitingPhase 1M.D. Anderson Cancer CenterNCT07655583One systemic option; omitting radiosurgery is testedReport a problem
- Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04410796In every armBoth arms take it while chemotherapy is addedWritten as OsimertinibReport a problem
- Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung CancerRecruitingPhase 3National Taiwan University HospitalNCT07738172In every armBoth arms take it while primary tumour resection is addedWritten as OsimertinibReport a problem
- Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerRecruitingPhase 3NRG OncologyNCT05624996In every armOne usual systemic option; SBRT is addedWritten as OsimertinibReport a problem
- EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLCRecruitingPhase 2Nanfang Hospital, Southern Medical UniversityNCT07637448One TKI; a PD-1 antibody is addedReport a problem
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT05642572In every armBoth arms take it with capmatinib while ramucirumab is addedWritten as OsimertinibReport a problem
- Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07505173Continued while hippocampus-protective radiotherapy is addedReport a problem
- Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung CancerRecruitingPhase 2Chinese University of Hong KongNCT07379476Both arms take it while radiotherapy is addedWritten as Osimertinib aloneReport a problem
- Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)RecruitingPhase 2Pusan National University HospitalNCT07073365After FLAURA2 induction while local therapy is addedReport a problem
- Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung CancerRecruitingNot applicableGuangzhou Medical UniversityNCT06304441In every armBoth arms take a TKI; intrathecal pemetrexed is addedWritten as OsimertinibReport a problem
- Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung CancerNot yet recruitingPhase 2Jianxing HeNCT07177092In every armBoth arms take it while primary tumour resection is addedWritten as OsimertinibReport a problem
- Orlistat Overcoming Third-generation EGFR-TKI ResistanceNot yet recruitingPhase 2Ping PengNCT06818955Continued while orlistat is added after resistanceReport a problem
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingPhase 1/2China Medical University HospitalNCT06071013In every armOne EGFR TKI; nintedanib is addedWritten as Nintedanib, gefitinib, erlotinib, afatinib, osimertinibReport a problem
- CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLCNot yet recruitingEarly Phase 1Second Affiliated Hospital of Nanchang UniversityNCT06557096In every armContinued while bevacizumab is added by spinal fluid CTCsWritten as Osimertinib 80 MGReport a problem
- A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Not yet recruitingPhase 2Peking Union Medical College HospitalNCT06142617In every armPlanned second line after chemotherapy and pembrolizumabWritten as OsimertinibReport a problem
Showing 20 of 42. See all 42 →
Beside a new treatment under test · 104 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with osimertinib: izalontamab brengitecan 7 · becotatug 5 · sacituzumab tirumotecan 4 · savolitinib 4 · glumetinib 4 · sapanisertib 2 · datopotamab deruxtecan 2 · vebreltinib 2
- A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLCRecruitingPhase 1/2Wayshine Biopharm, Inc.NCT07206498In every armPartner of new WSD0922-FUWritten as Osimertinib (Tagrisso®)Report a problem
- Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)RecruitingPhase 3Bristol-Myers SquibbNCT07680790In every armPartner of new iza-bren; also in the comparatorWritten as OsimertinibReport a problem
- A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver GenesRecruitingPhase 1/2Sichuan Huiyu Pharmaceutical Co., LtdNCT06712680In every armPartner of new HYP-6589Written as OsimertinibReport a problem
- A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3AbbVieNCT07005102In every armPartner of new telisotuzumab adizutecanWritten as Osimertinib (Osi)Report a problem
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3AbbVieNCT07155187Partner of new telisotuzumab adizutecan in two armsWritten as OsimertinibReport a problem
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsRecruitingPhase 1/2Bristol-Myers SquibbNCT06618287Partner of new BMS-986507Written as OsimertinibReport a problem
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibRecruitingPhase 1/2Genprex, Inc.NCT04486833Partner of new quaratusugene ozeplasmidWritten as osimertinibReport a problem
- Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung CancerRecruitingPhase 1Ohio State University Comprehensive Cancer CenterNCT04780568In every armPartner of new tegavivintWritten as OsimertinibReport a problem
- A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07640789In every armBoth arms take it while new BL-B01D1 is addedWritten as OsimertinibReport a problem
- A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07622186Partner of new SKB571Written as OsimertinibReport a problem
- Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 3AstraZenecaNCT06350097In every armBoth arms take it while new Dato-DXd is addedWritten as OsimertinibReport a problem
- Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07329322In every armPartner of new sacituzumab tirumotecan before surgeryWritten as OsimertinibReport a problem
- Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung CancerRecruitingPhase 1Karen Reckamp, MD, MSNCT05401110In every armPartner of new carotuximabWritten as OsimertinibReport a problem
- A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)RecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07642024Partner of new BL-B01D1; alone in one comparator armWritten as OsimertinibReport a problem
- Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung CancerRecruitingPhase 1BioNTech SENCT05142189Partner of new BNT116 in one cohortWritten as OsimertinibReport a problem
- A Phase 2 Study of ABSK043 Combined With OsimertinibNot yet recruitingPhase 2Abbisko Therapeutics Co, LtdNCT07710612In every armPartner of new ABSK043Written as ABSK043 in combination with OsimertinibReport a problem
- A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerRecruitingPhase 2AkesoNCT07669779Partner of new AK146D1Written as OsimertinibReport a problem
- A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07535437Partner of new ivonescimab in one cohortWritten as OsimertinibReport a problem
- Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerRecruitingPhase 1Nuvectis Pharma, Inc.NCT07315113In every armPartner of new NXP900Written as OsimertinibReport a problem
- Zorifertinib With Osimertinib for NSCLC With Meningeal ProgressionRecruitingPhase 1Alpha Biopharma (Jiangsu) Co., Ltd.NCT07361705In every armPartner of new zorifertinib for meningeal progressionWritten as Zorifertinib and Osimertinib Combination TherapyReport a problem
Showing 20 of 104. See all 104 →
Beside supportive care · 1 — a supportive treatment or test is studied
- A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)RecruitingNot applicableIntergroupe Francophone de Cancerologie ThoraciqueNCT06053099Standard adjuvant treatment; resistance markers studiedReport a problem
One option of several · 3 — a test or a strategy chooses among drugs
- Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent SystemNot yet recruitingPhase 4NING LINCT06824792One drug an AI system can chooseReport a problem
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491One drug the organoid test can chooseWritten as OsimertinibReport a problem
- Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell CarcinomaStatus unknownPhase 2Herlev and Gentofte HospitalNCT04644432One drug a tailored kidney cancer strategy can chooseReport a problem
Given beside what is tested · 1 — usual care or a partner of the new treatment
As the comparator · 17 — what is tested is compared with osimertinib
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingPhase 3ArriVent BioPharma, Inc.NCT07185997One investigator's-choice comparator against firmonertinibReport a problem
- ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLCNot yet recruitingPhase 3Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT07897188With chemotherapy, a comparator for new ASKC202Written as osimertinibReport a problem
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)RecruitingPhase 1/2Dizal PharmaceuticalsNCT07079475Comparator for new DZD6008 with sunvozertinibWritten as OsimertinibReport a problem
- TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesRecruitingPhase 2TYK Medicines, IncNCT05948813Comparator for new TY-9591 in brain metastasesWritten as OsimertinibReport a problem
- A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruitingPhase 3Allist Pharmaceuticals, Inc.NCT06970639Comparator for furmonertinib with chemotherapyWritten as Osimertinib Mesylate TabletsReport a problem
- Therapy for Advanced NSCLC With EGFR 19delins MutationNot yet recruitingEarly Phase 1Fuzhou General HospitalNCT07458919One control-group TKI against first-generation TKIsReport a problem
- A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung CancerNot yet recruitingPhase 1/2Beijing Pearl Biotechnology Limited Liability CompanyNCT07285148With ANS014004, the comparator for new PLB1004Written as ANS014004 + OsimertinibReport a problem
- A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerRecruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07229729One TKI option in the control against new SHR-A2102Written as Osimertinib MesylateReport a problem
- Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.RecruitingPhase 2Avistone Biotechnology Co., Ltd.NCT06574347Comparator for new vebreltinib with PLB1004Written as OsimertinibReport a problem
- Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung CancerNot yet recruitingPhase 2Peking Union Medical College HospitalNCT06752408Comparator for aumolertinib, first-lineWritten as OsimertinibReport a problem
- High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain MetastasesNot yet recruitingPhase 2Taizhou HospitalNCT06319950Comparator for high-dose furmonertinib in brain metastasesWritten as OsimertinibReport a problem
- Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)RecruitingPhase 3TYK Medicines, IncNCT05382728Comparator for new TY-9591 (FLETEO)Written as OsimertinibReport a problem
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04487080Comparator for amivantamab and lazertinib (MARIPOSA)Written as OsimertinibReport a problem
- AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLCActive, not recruitingPhase 4Michael HoppNCT04413201Upfront comparator against afatinib then osimertinibWritten as OsimertinibReport a problem
- Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung CancerTerminatedPhase 3EQRx International, Inc.NCT05493501Comparator for aumolertinib, alone or with chemotherapyReport a problem
- A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy VolunteersCompletedPhase 1TYK Medicines, IncNCT04798638Reference for new TY-9591's drug levels in volunteersWritten as Osimertinib Mesylate Tablets under Fasted Condition - Arm1Report a problem
- Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesStatus unknownPhase 3Shanghai Chest HospitalNCT04870190Comparator for new aumolertinib in brain metastasesWritten as OsimertinibReport a problem
Observed · 58 — patients on it are followed, or it is given outside a trial
- UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ AllianceRecruitingAstraZenecaNCT06726720One AstraZeneca drug patients may start, observedReport a problem
- A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLCRecruitingBeijing Cancer Prevention & Treatment SocietyNCT06422546Report a problem
- Barriers and Facilitators of Persistence With Adjuvant OsimertinibRecruitingAstraZenecaNCT07542210Persistence with adjuvant treatmentReport a problem
- OSIREAL - Osimertinib RWE on EGFRm NSCLC in SpainRecruitingAstraZenecaNCT06068049Real-world use in Spain (OSIREAL)Report a problem
- Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLCRecruitingTongji HospitalNCT07837739Among adjuvant TKIs, observedReport a problem
- Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung CancerRecruitingN-Power MedicineNCT07028489External control cohort, first-line options observedReport a problem
- Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC PatientsRecruitingGruppo Oncologico Italiano di Ricerca ClinicaNCT07363252Recurrence mechanisms after adjuvant treatmentWritten as OsimertinibReport a problem
- A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer PatientsNot yet recruitingGuangzhou University of Traditional Chinese MedicineNCT07338396Among EGFR TKIs, TCM syndromes observedReport a problem
- Osimertinib for Advanced EGFR-positive NSCLC PatientsRecruitingNational University Hospital, SingaporeNCT05037331One oral drug whose value is assessedReport a problem
- Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLCRecruitingHunan Province Tumor HospitalNCT04324164Among third-generation TKIs, uncommon mutationsReport a problem
- Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)RecruitingSecond Xiangya Hospital of Central South UniversityNCT05598528Among third-generation TKIs, primary resistanceReport a problem
- AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain MetastasesRecruitingFudan UniversityNCT06604689Among third-generation TKIs, AI prognosisReport a problem
- ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerRecruitingFondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06532149One targeted drug; sexual health studiedWritten as OsimertinibReport a problem
- LAT for Oligoprogressive NSCLC Treated With First-line OSImertinibRecruitingUniversitaire Ziekenhuizen KU LeuvenNCT04216121Local therapy for oligoprogression on it, observedReport a problem
- Efficacy of Osimertinib in Patients With Lung CancerRecruitingHunan Province Tumor HospitalNCT06174857In uncommon EGFR mutations, observedReport a problem
- A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients TreatmentRecruitingSun Yat-sen UniversityNCT01994057Among EGFR TKIs, outcomes reviewedReport a problem
- Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung CancerActive, not recruitingHellenic Cooperative Oncology GroupNCT05127382Real-world first-line use in GreeceReport a problem
- Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung AdenocarcinomaCompletedLaibin People's HospitalNCT07857694Among TKIs with thoracic radiotherapy, observedReport a problem
- Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC PatientsActive, not recruitingPrECOG, LLC.NCT06538038With or without chemotherapy, observedWritten as OsimertinibReport a problem
- Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCActive, not recruitingAstraZenecaNCT06376084With chemotherapy first-line, observedReport a problem
Showing 20 of 58. See all 58 →
As a tool · 2 — an imaging tracer or a test of drug response
- Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerNot yet recruitingEarly Phase 1Oliver JonasNCT07892300One drug in a microdevice measuring local responseReport a problem
- Implantable Microdevice In Primary Brain TumorsRecruitingEarly Phase 1Oliver JonasNCT04135807One drug in a microdevice measuring local responseReport a problem
Codes
What other systems call osimertinib · ClinicalTrials.gg INT000195
- MeSH (NLM) C000596361osimertinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3C06JJ0Z2OOSIMERTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1721560Confirmed FDA, Wikidata
- Wikidata Q21506464osimertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116377OsimertinibOne source FDA
- DrugBank DB09330One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000596361 | osimertinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3C06JJ0Z2O | OSIMERTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1721560 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21506464 | osimertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116377 | Osimertinib | One source FDA |
| DrugBank | DB09330 | — | One source Wikidata |
Also registered as osimertinib mesylate (UNII RDL94R2A16 · RxNorm 1721559).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.